Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03383627 · ClinicalTrials.gov registry record · NA

Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

A NA study of Diabetes and Kidney Diseases, sponsored by Northwell Health.

Completed
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT03383627 is a NA study of Diabetes and Kidney Diseases that has completed, run by Northwell Health. The registered enrollment target is 80 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03383627, a NA study of Diabetes and Kidney Diseases, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Diabetes control is often assessed by tests of glucose levels over time, such as the glycosylated hemoglobin A1c (HbA1c) and fructosamine. In the later stages of chronic kidney disease (CKD) there is limited data available on the utility of these tests. There are reasons to believe that the tests may be less accurate in this population. Continuous glucose monitoring (CGM) offers an effective method for understanding the totality of glucose exposure and incidence of both hyperglycemic and hypoglycemic excursions.

Conditions Studied

Interventions

  • DEVICE Continuous Glucose Monitoring

Study Locations (1)

New York

  • Northwell Health (Division Endocrinology and Nephrology) - Great Neck

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2017-11-30
Est. Completion 2018-08-21
Phase NA

Sponsor

Northwell Health

370 total trials

What the Registry Record Tells You About NCT03383627

The ClinicalTrials.gov registry entry for NCT03383627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitoring is the first listed.

NCT03383627 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03383627 about?

NCT03383627 is a clinical study titled "Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease". Diabetes control is often assessed by tests of glucose levels over time, such as the glycosylated hemoglobin A1c (HbA1c) and fructosamine. In the later stages of chronic kidney disease (CKD) there is limited data available on the utility of these tests. There are reasons to believe that the tests ma...

What is the current status of trial NCT03383627?

This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2017-11-30. Estimated completion is 2018-08-21.

What conditions does trial NCT03383627 study?

This clinical trial studies the following conditions: Diabetes, Kidney Diseases.

What interventions are being tested in trial NCT03383627?

The interventions under investigation include: Continuous Glucose Monitoring (DEVICE).

Who is sponsoring clinical trial NCT03383627?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03383627 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.